HC Wainwright Reiterates “Buy” Rating for Shattuck Labs (NASDAQ:STTK)

HC Wainwright reiterated their buy rating on shares of Shattuck Labs (NASDAQ:STTKFree Report) in a report published on Friday, Benzinga reports. The brokerage currently has a $28.00 target price on the stock. HC Wainwright also issued estimates for Shattuck Labs’ Q1 2024 earnings at ($0.43) EPS, Q2 2024 earnings at ($0.44) EPS, Q3 2024 earnings at ($0.48) EPS and Q4 2024 earnings at ($0.51) EPS.

Separately, Needham & Company LLC reissued a buy rating and set a $12.00 target price on shares of Shattuck Labs in a report on Friday.

Read Our Latest Report on STTK

Shattuck Labs Stock Down 1.9 %

STTK opened at $9.47 on Friday. The firm’s fifty day moving average price is $8.99 and its 200 day moving average price is $4.68. Shattuck Labs has a 12-month low of $1.33 and a 12-month high of $10.66.

Insiders Place Their Bets

In other Shattuck Labs news, CFO Andrew R. Neill sold 25,000 shares of the stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. Following the sale, the chief financial officer now directly owns 173,446 shares of the company’s stock, valued at $1,734,460. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.46% of the stock is owned by corporate insiders.

Institutional Trading of Shattuck Labs

Large investors have recently modified their holdings of the company. Prosight Management LP increased its holdings in shares of Shattuck Labs by 4.4% in the 2nd quarter. Prosight Management LP now owns 2,109,620 shares of the company’s stock worth $6,582,000 after acquiring an additional 87,952 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Shattuck Labs in the 1st quarter worth about $73,000. Tower Research Capital LLC TRC increased its holdings in shares of Shattuck Labs by 2,785.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 23,287 shares of the company’s stock worth $63,000 after acquiring an additional 22,480 shares during the period. Jane Street Group LLC acquired a new stake in shares of Shattuck Labs in the 1st quarter worth about $58,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Shattuck Labs in the 1st quarter worth about $37,000. Institutional investors and hedge funds own 48.63% of the company’s stock.

Shattuck Labs Company Profile

(Get Free Report)

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

Recommended Stories

Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.